Relationship between FDG-PET and GLUT-1 immunostaining of primary musculoskeletal tumors.

原发性肌肉骨骼肿瘤的 FDG-PET 和 GLUT-1 免疫染色之间的关系。

• 批准号: 14570836
• 负责人: AOKI Jun
• 金额: $ 2.05万
• 依托单位: Gunma University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570836/
• 关键词: Glucose; Positron CT (PET); Bone tumor; Soft tissue tumor; Histiocyte; FAMT; FDG; ポジトロンCT (PET)

Positron emission tomography (PET) can provide an in vivo method for evaluating metabolism and physiology in normal and diseased tissues. Clinical trials with [18F] 2-deoxy-2-fluoro-D-glucose (FDG), the most commonly used radiolabeled tracer for PET imaging, have demonstrated increased accumulation of FDG in several cancer tissues. Recent reports and our own experiences suggest that FDG-PET might not accurately reflect malignant potential of musculoskeletal tumors, but rather implicate cellular components included in the lesions. A high accumulation of FDG can be observed in histiocytic, fibroblastic, and some neurogenic lesions, regardless of whether they are benign or malignant.In this research project, we have tried to compare FDG uptake on PET study to glucose transporter-1 (GLUT-1) immunostaining of musculoskeletal tumors. For the first step, we have selected histiocytic tumors (malignant fibrous histiocytoma, giant cell tumor of bone and tendon sheath, non-ossifying fibroma, sarcoidosis, Langerhans cell histiocytosis, etc.) for the immunohistochemistry. So far, the immunostaining is not technically stable for formalin-fixed and paraffin-embedded sections. So, recently, we are trying the staining for sections of fresh specimens.The mechanism of FDG uptake in musculoskeletal tumors is continuously to be investigated, because we should know whether FDG-PET can be a screening method for differential diagnosis between benign and malignant musculoskeletal lesions, including many neoplasms originating from different tissues altogether.

正电子发射断层扫描（PET）可以提供一种体内方法，用于评估正常和病变组织中的代谢和生理学。[18 F] 2-脱氧-2-氟-D-葡萄糖（FDG）是PET成像中最常用的放射性标记示踪剂，其临床试验表明FDG在几种癌症组织中的蓄积增加。最近的报告和我们自己的经验表明，FDG-PET可能无法准确反映肌肉骨骼肿瘤的恶性潜能，而是涉及病变中包含的细胞成分。在组织细胞、成纤维细胞和一些神经源性病变中，无论是良性还是恶性，都可以观察到FDG的高蓄积。在本研究项目中，我们试图比较肌肉骨骼肿瘤的PET研究和葡萄糖转运蛋白-1（GLUT-1）免疫染色对FDG摄取的影响。第一步，我们选择了组织细胞肿瘤（恶性纤维组织细胞瘤、骨和腱鞘巨细胞瘤、非骨化性纤维瘤、结节病、郎格罕细胞组织细胞增生症等）。免疫组织化学。到目前为止，福尔马林固定和石蜡包埋切片的免疫染色在技术上还不稳定。因此，近年来，我们尝试对新鲜标本切片进行染色，并对骨骼肌肿瘤的FDG摄取机制进行持续研究，因为我们需要知道FDG-PET是否可以作为鉴别骨骼肌良恶性病变的筛查方法，包括许多起源于不同组织的肿瘤。

项目成果

Aoki, J.: "FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses."Skeletal Radiol.. 32. 133-138 (2003)

Aoki, J.：“FDG-PET 用于良性和恶性软组织肿块的术前鉴别诊断。”Skeletal Radiol.. 32. 133-138 (2003)

Aoki, J.: "FDG-PET for evaluating musculoskeletal tumors : a review."J Orthop Sci.. 8. 435-441 (2003)

Aoki, J.：“FDG-PET 用于评估肌肉骨骼肿瘤：综述。”J Orthop Sci.. 8. 435-441 (2003)

Kato, K.: "Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase."Annals of Nuclear Medicine. 17. 41-46 (2003)

Kato, K.：“FDG-PET 在急性至亚急性期良性和恶性骨折鉴别诊断中的应用。”核医学年鉴。

Kato, K.: "Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase."Ann Nucl Med. 17. 41-46 (2003)

Kato, K.：“FDG-PET 在急性至亚急性期良性和恶性骨折鉴别诊断中的应用。”Ann Nucl Med。

青木 純: "骨・軟部腫瘍へのアプローチ"画像診断. 23. 624-635 (2003)

Jun Aoki：“骨和软组织肿瘤的方法”影像诊断。23。624-635（2003）。